Why Inspire Medical Systems stock is in focus now

Inspire Medical Systems (INSP) is drawing closer scrutiny after initiating voluntary Class II recalls for two core device components because of incorrect Use By labeling, which could lead to product degradation and premature revision surgery.

The recalls cover selected units of the Inspire Stimulation Lead and the Inspire Respiratory Sensing Lead distributed in the US and Hong Kong, and they remain ongoing as regulators track the company’s response and remediation steps.

The voluntary recalls and index reshuffle around Inspire Medical Systems have arrived alongside a sharp rebound in the 1 month share price, up 20.05%. This comes against a much weaker backdrop, with the year to date share price return down 46.41% and the 1 year total shareholder return down 61.04%, suggesting recent momentum is picking up after a prolonged period of pressure.

If product recalls and index changes have you reassessing healthcare exposure, it can help to widen your search using a focused list of healthcare AI opportunities such as 40 healthcare AI stocks

With Inspire Medical Systems rebounding sharply after heavy 1 year declines, index reclassification and product recalls are pulling in opposite directions. Does the current share price better reflect business fundamentals, or is it a sentiment swing that could fade as valuation is tested next?

Most Popular Narrative: 5.2% Undervalued

The most widely followed narrative for Inspire Medical Systems currently points to a fair value of about $52.17 versus the last close at $49.45, framing the stock as modestly undervalued and hinging heavily on how reimbursement, coding and growth assumptions play out over the next several years.

The recent delay in transitioning centers to the Inspire V next-generation system, including slower onboarding, delayed SleepSync implementation, and the Medicare billing update, are transitory issues; as these barriers resolve (with Medicare billing now live and most centers expected to complete onboarding by end of Q3), procedure volumes and revenue growth are positioned to reaccelerate in 2026 as pent up demand is realized.

Want to see what sits behind that confidence in Inspire Medical Systems? The narrative leans on a specific revenue path, shifting margins and a valuation multiple that all need to line up. The full story is in how those three levers interact over time, not just where the share price is today.

Result: Fair Value of $52.17 (UNDERVALUED)

However, Inspire Medical Systems still faces meaningful risks, including slower than expected Inspire V rollout and ongoing reimbursement and coding uncertainty that could undermine the current undervaluation case.

Next Steps

Given the mixed sentiment around Inspire Medical Systems, with both risks and rewards in play, it makes sense to move quickly and review the underlying data yourself using our breakdown of 3 key rewards and 2 important warning signs

Looking for more investment ideas beyond Inspire Medical Systems?

If Inspire Medical Systems has your attention, do not stop there. Broaden your watchlist with other opportunities that fit different goals and risk levels.

• Target potential mispricing by reviewing companies highlighted in the 41 high quality undervalued stocks and see which ones deserve a closer look next.
• Strengthen your income focus by scanning stocks in the 8 dividend fortresses and compare yields, payout histories, and business quality in one place.
• Prioritise resilience by checking companies featured in the 74 resilient stocks with low risk scores and see which profiles best match your comfort with downside risk.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.